51. Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear
- Author
-
Vogels, R, Macagno, N, Griewank, K, Groenen, P, Verdijk, M, Fonville, J, Kusters, B, Figarella-Branger, D, Wesseling, P, Bouvier, C, Flucke, U, Cornu, P, Dufour, H, Guyotat, J, Jouvet, A, Metellus, P, Mokhtari, K, Vasiljevic, A, Varlet, P, Bekers, E, Djafarihamedani, M, Kurt, E, Kusters-Vandevelde, H, Fleischeuer, R, Leenstra, Sieger, Robe, P, Spliet, W, Troost, D, van Furth, W, Radboud University Medical Center [Nijmegen], Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de Neuropathologie [AP-HM Hôpital de la Timone], Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital Essen, Stichting PAMM, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Service d’Anatomie Pathologique et de Neuropathologie, APHM, Hôpital de la Timone, Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU), VU University Medical Center [Amsterdam], AUTRES, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Pathology, CCA - Imaging and biomarkers, and Neurosurgery
- Subjects
Solitary fibrous tumor ,Medizin ,Clinical Neurology ,Nab2 stat6 ,Biology ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,medicine.disease_cause ,Pathology and Forensic Medicine ,Central Nervous System Neoplasms ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,medicine ,Humans ,Oncogene Fusion ,Promoter Regions, Genetic ,Telomerase ,Retrospective Studies ,030304 developmental biology ,0303 health sciences ,Mutation ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,Promoter ,Prognosis ,medicine.disease ,Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] ,Progression-Free Survival ,3. Good health ,Clinical neurology ,Repressor Proteins ,Survival Rate ,Solitary Fibrous Tumors ,030220 oncology & carcinogenesis ,Cancer research ,Neurology (clinical) ,STAT6 Transcription Factor ,Hemangiopericytoma - Abstract
International audience; Grading of meningeal solitary fibrous tumors/hemangiopericytomas(SFTs/HPCs) of the central nervous system (CNS)is nowadays based on histologic criteria as described in therevised fourth edition of the WHO Classification of CNStumors [10] or the more recently published, updated versionof the Marseille Grading System (MGS) [11]. Histologybasedgrading of CNS SFTs/HPCs allows for discriminatingsubgroups with significant differences in prognosis. However,the often-piecemealresection of these tumors mayhamper adequate evaluation of mitotic activity and necrosis,and thereby assessment of malignancy grade. NAB2–STAT6fusion is the molecular hallmark of both soft tissue SFTs andCNS SFTs/HPCs, and the resultingfusion protein accumulatesin the nucleus and acts as a transcriptional activatorof early growth response mediated pathways with STAT6immunohistochemistry being a very sensitive and specifictool for their diagnosis [5, 8, 12, 14]. For soft tissue SFTs,particular NAB2–STAT6 fusion variants as well as telomerasereverse transcriptase (TERT) promoter mutations leadingto telomerase activity and tumor cell immortalization havebeen reported to have prognostic value. Some studies haveincluded CNS SFTs/HPCs in their cohort, but because ofsmall numbers and lack of (long term) follow-up data theprognostic value of these markers for CNS SFTs/HPCs isstill unclear.
- Published
- 2019